First sales of GI specialty products
RedHill’s strategy to diversify into commercial specialty pharma business has born first fruits with initial sales booked in Q217, in line with previously guided timelines to initiate the marketing activities. The US organisation is now fully set up and markets two GI products: Donnatal (co-promoted with Concordia Healthcare) and EnteraGam (exclusive licence to sell from Entera Health). We now include the two products in our RedHill valuation, which is increased to $414m or $23.4/ADS. Notably, RedHill recently added a third product, Esomeprazole Strontium, to its US portfolio, which we could potentially add to our valuation assuming successful initiation of promotional activities in coming weeks.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.